Aptar Pharma, a global leader in drug delivery and active material science solutions and services, today announced that it has entered into an exclusive collaboration agreement with Pulmotree to lead the development and promotion of their Kolibri Non-Propellant Liquid Inhaler (NPLI) platform.

As part of the agreement, Aptar Pharma will provide PULMOTREE with their full support to accelerate growth, be the main point of contact for customers, and have the ability to complement the Kolibri™ NPLI Platform Technology with Aptar’s suite of comprehensive services.

Non-Propellant Liquid Inhalers encompass nebulizers and soft-mist inhalers, and are being developed as an alternative to propellant-based systems.

Howard Burnett, Vice President, Global Pulmonary Category, Aptar Pharma, stated, “Pulmotree has solid experience in the NPLI field and Aptar Pharma is delighted to be able to offer the Kolibri™ technology in collaboration with such a knowledgeable partner, to be able to provide full support to all drug developers, from formulation development to patient onboarding.”

Ulf Krüger, CEO of PULMOTREE, stated, “With this alliance, pharmaceutical partners can access an unprecedented portfolio of services from Aptar Pharma as a single source, in the development of combination products to accelerate product development.  For PULMOTREE, this important step enables us to continue to grow sustainably and expand our portfolio.”